SLC5A2 and type 2 diabetes mellitus: To our knowledge, this is the first report discussing the risk of EDKA with the use of GLP1 receptor agonists together with SGLT2 inhibitors and the extreme restriction of carbohydrate intake in type 2 diabetes patients in Saudi Arabia.